Surmodics’ (SRDX) Underperform Rating Reiterated at Barrington Research

Barrington Research reiterated their underperform rating on shares of Surmodics (NASDAQ:SRDX) in a report issued on Friday morning, MarketBeat.com reports.

SRDX has been the topic of a number of other reports. Zacks Research raised shares of Surmodics to a “hold” rating in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surmodics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $43.00.

Surmodics Stock Performance

Shares of Surmodics stock opened at $41.61 on Friday. The company has a market cap of $594.94 million, a PE ratio of -33.83 and a beta of 1.30. Surmodics has a 52 week low of $25.87 and a 52 week high of $41.75. The business has a 50 day moving average price of $30.28 and a 200-day moving average price of $31.08. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On Surmodics

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in Surmodics by 65.4% during the third quarter. CWM LLC now owns 1,047 shares of the company’s stock worth $31,000 after buying an additional 414 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Surmodics by 705.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $37,000 after purchasing an additional 1,080 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Surmodics by 67.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company’s stock worth $43,000 after purchasing an additional 579 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Surmodics by 289.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company’s stock worth $51,000 after purchasing an additional 1,286 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Surmodics in the third quarter valued at approximately $101,000. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).